SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-22-000022
Filing Date
2022-03-11
Accepted
2022-03-11 16:46:52
Documents
14
Period of Report
2022-03-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20220310.htm   iXBRL 8-K 41351
2 EX-10.1 summit-notepurchaseagreeme.htm EX-10.1 132499
3 EX-10.2 summit-promissorynote4867x.htm EX-10.2 38842
  Complete submission text file 0001599298-22-000022.txt   385209

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20220310.xsd EX-101.SCH 1905
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20220310_lab.xml EX-101.LAB 23832
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20220310_pre.xml EX-101.PRE 12510
8 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20220310_htm.xml XML 11089
Mailing Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 22733761
SIC: 2834 Pharmaceutical Preparations